Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-252

@DocMcstuffins

$1.5billion is awfully high for a company that currently doesn't have much of a path to medium term revenue or FDA approval

okay now you are just taking the piss, or you are now also a chartered financial analyst too (if so show your working?). I would say that is probably right for a company looking at a single indicator for a small market doing it on their own, but Mesoblast have numerous partnerships already (tasly, grunenthal, Novartis), have wrapped up 3 phase 3 trials (one is still in dispute), where 2 of these are monstrous multi $b markets and yielded pretty damn good results which could support funded trials/additional partnerships. There's another indicator on covid ards but let's conservatively leave that aside... Oh yeah plus we are getting revenue from Temcel in Japan. $1.5b is piss for this company, and many analysts agree with their valuations several multiples of the current market price, or they are all wrong (bell Potter, Dawson James, maxim group, Cantor...) And you are right? I know which way I'm betting....